Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Nicardipine

Nicardipine

Nicardipine is a calcium channel blocker used to treat hypertension and angina pectoris.
It relaxes blood vessels and reduces the workload on the heart, resulting in improved blood flow and oxygen supply.
Nicardipine is also studied for its potential neuroprotective effects in conditions like stroke and Alzheimer's disease.
Researchers can leverage PubCompare.ai's AI-driven platform to optimize their Nicardipine research, locate relevant protocols from literature, preprints, and patents, and identify the best procedures for enhanced reproducibility and accuary.

Most cited protocols related to «Nicardipine»

1
Isolation and Characterization of Rabbit Ventricular Cardiomyocytes
Cited 6 times
Rabbit left ventricular cardiomyocytes were isolated enzymatically as prescribed previously.21 (link) Only cardiomyocytes with smooth and glossy edges and surfaces, clear transverse striations, and that could be stably voltage-clamped for 8 min without significant contraction were used. Seal resistance was above 1GΩ with less than 10 % variability. Currents were obtained with a patch-clamp amplifier (EPC-10, Heka Electronic, Lambrecht, Pfalz, Germany), filtered at 1 kHz and digitized at 10 kHz. During recording of late INa, the bath solution contained (in mmol/L):135 NaCl, 5.4 CsCl2, 1.8 CaCl2, 1 MgCl2, 0.3 BaCl2, 0.33 NaH2PO4, 10 glucose, 10 HEPES, 0.001 nicardipine, pH 7.3. The patch pipette solution contained (in mmol/L):120 CsCl2, 1.0 CaCl2, 5 MgCl2, 5 Na2ATP, 10 TEACl, 11 EGTA, 10 HEPES (pH 7.3, adjusted with CsOH). All experiments were carried out at a temperature of 23±1 °C.
To elicit a late INa in a single cell, twenty 300-ms depolarizing pulses to -20 mV from a holding potential of -90 mV were applied at CLs of 500, 667, 1000, 2000 and 4000 ms using a serial repeated-measurement protocol, with 3 min between each change of stimulation CL, during which membrane potential was held at -90 mV. In cardiomyocytes isolated from 8 rabbit hearts, the amplitude of late INa was measured at 200 ms after initiation of the depolarization step before (control, no drug) and 3 min after exposure of a myocyte to 1 and 4 μmol/L TTX, respectively.
Wu L., Ma J., Li H., Wang C., Grandi E., Zhang P., Luo A., Bers D.M., Shryock J.C, & Belardinelli L. (2011). Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation, 123(16), 1713-1720.
Publication 2011
A 300 ARID1A protein, human barium chloride Bath Cells Egtazic Acid Glucose Heart HEPES Left Ventricles Magnesium Chloride Membrane Potentials Muscle Cells Myocytes, Cardiac Nicardipine Pharmaceutical Preparations Phocidae Pulses Rabbits Sodium Chloride
2
In situ Ca2+ Imaging of Intestinal ICC
Cited 5 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2018
Action Potentials Cardiac Arrest Equus asinus Intestines Intestines, Small Lens, Crystalline Microscopy Muscle Tissue Nicardipine Pharmaceutical Preparations Smooth Muscles
3
Hypertension Management in Acute Stroke
Cited 4 times
The goal of treatment was to reduce and maintain the hourly minimum systolic blood pressure in the range of 140 to 179 mm Hg in the standard-treatment group and in the range of 110 to 139 mm Hg in the intensive-treatment group throughout the period of 24 hours after randomization. Before randomization, intravenous anti-hypertensive medication, including nicardipine, could be administered to lower the systolic blood pressure to less than 180 mm Hg,12 (link) but patients were not eligible if the systolic blood pressure was lowered to less than 140 mm Hg. After randomization, nicardipine, administered by intravenous infusion, was the first-line antihypertensive agent and was initiated at a dose of 5 mg per hour, which was then increased by 2.5 mg per hour every 15 minutes as needed, up to a maximum dose of 15 mg per hour. If the systolic blood-pressure level was higher than the target, despite infusion of the maximum dose of nicardipine for 30 minutes, a prespecified second agent, intravenous labetalol, was used. In countries where labetalol was not available, intravenous diltiazem or urapidil was used. Additional care was based on the best available evidence15 (link) and the guidelines from the American Stroke Association Stroke Council12 (link) and the European Stroke Initiative Writing Committee.16 (link)We assessed the success, or lack thereof, of the reduction in the systolic blood-pressure level. Primary treatment failure was defined as not reaching the target systolic blood pressure of less than 140 mm Hg in the intensive-treatment group and less than 180 mm Hg in the standard-treatment group within 2 hours after randomization. Secondary treatment failure was defined as the hourly minimum systolic blood pressure remaining higher than the upper limit of the target range for 2 consecutive hours during the period of 2 to 24 hours after randomization. No effort was made to conceal the treatment assignment from the participants or treating physicians.
Qureshi A.I., Palesch Y.Y., Barsan W.G., Hanley D.F., Hsu C.Y., Martin R.L., Moy C.S., Silbergleit R., Steiner T., Suarez J.I., Toyoda K., Wang Y., Yamamoto H, & Yoon B.W. (2016). Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. The New England journal of medicine, 375(11), 1033-1043.
Publication 2016
Antihypertensive Agents Cerebrovascular Accident Diltiazem Europeans Intravenous Infusion Labetalol Nicardipine Patients Physicians Systole Systolic Pressure urapidil
4
Single-Channel Recording of Glomerular Ion Channels
Cited 4 times
Cover glasses that contained glomeruli were placed into a perfusion chamber
mounted on an inverted Nikon Ti-S microscope and superfused with a physiologic saline
solution (pH 7.4). Single-channel current data were acquired as described
previously.19 (link),20 (link) After a high resistance seal was obtained, cell-attached
recording was performed immediately. The membrane resistance was monitored regularly to
ensure the quality of recording. For measurements of acute effect only one experiment was
performed per dish to avoid any possibility of examining cells whose properties might have
been altered by extended exposure to Ang II. The recordings were made in symmetric
chloride solutions. The bath solution consisted of 126 NaCl, 1 CaCl2, 10 HEPES,
2 MgCl2, 10 glucose, pH 7.4. The pipette solution contained 126 NaCl, 1.5
CaCl2, 10 HEPES, 10 glucose; pH7.4; plus added directly before the
patch-clamp experiments were 100 µM niflumic acid or DIDS (to block
Ca2+-activated Cl− channels), 10 mM TEA (to inhibit
large-conductance Ca2+-dependent K+ channel), 10 nM iberiotoxin (to
block Ca2+-activated K+ channels), 10 µM nicardipine (to
block N-type Ca2+ channels). During the patch-clamp measurements in the
single-channel mode the activity of the ion channels was first monitored in response to
the potential applied in steps of 10 or 20 mV in the range of – 90 mV to + 60 mV
in order to estimate the channel’s conductance and I-V relationship. After that,
the voltage was clamped at – 60 mV and the channels’ activity was recorded
for several minutes before the drugs were applied.
Ilatovskaya D.V., Palygin O., Chubinskiy-Nadezhdin V., Negulyaev Y.A., Ma R., Birnbaumer L, & Staruschenko A. (2014). Angiotensin II has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli. Kidney international, 86(3), 506-514.
Publication 2014
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid Bath Calcium-Activated Potassium Channel Cells Eyeglasses Glucose HEPES Hyperostosis, Diffuse Idiopathic Skeletal iberiotoxin Ion Channel Kidney Glomerulus Magnesium Chloride Microscopy Nicardipine Niflumic Acid Perfusion Pharmaceutical Preparations Phocidae physiology Sodium Chloride Tissue, Membrane
5
Integrated FAERS and JADER Databases
Cited 3 times
The US Food and Drug Administration (FDA) adverse event reporting system (FAERS) is an SRS and the largest and best-known database worldwide. The regulatory authority in Japan, the Pharmaceuticals and Medical Devices Agency (PMDA), controls the SRS of the JADER database. Adverse events recorded in the FAERS database from January 2004 to June 2014 were downloaded from the FDA website (http://www.fda.gov). Relevant information from the JADER database from April 2004 to November 2016 was downloaded from the PMDA website (http://www.pmda.go.jp). We constructed a database that integrated each FAERS and JADER dataset using the FileMaker Pro 13 (FileMaker Inc.). For duplicate entries, we followed the FDA recommendation (http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects), and adopted the most recent case number to identify duplicate patient reports and excluded them from the analysis.
We analyzed four immunosuppressants (CsA, everolimus, sirolimus, and mycophenolate mofetil), four calcium channel blockers (amlodipine, benidipine, nicardipine and nifedipine), and 11 anticonvulsants (carbamazepine, clobazam, diazepam, gabapentin, levetiracetam, phenobarbital, phenytoin, primidone, topiramate, valproic acid, and zonisamide). For drug definitions, we used both the general and brand names based on the DrugBank 3.0 and 4.0 (Table 1). Drugs in the FAERS were classified into four categories: Primary Suspect drug (PS), Secondary Suspect drug (SS), Concomitant (C), and Interacting (I); according to their anticipated degree of involvement in adverse events. The analysis was restricted to reports where drugs were recorded as PS and SS in the FAERS database. In the “drug information” table of the JADER database, each drug was assigned a code according to its association with adverse drug reactions: “suspected drug,” “concomitant drug,” or “interacting drug.” The analysis was restricted to reports where drugs were recorded as “suspected drugs” in the JADER database.

Brand names of drugs

Generic nameaNumber of brand nameBrand name
Immunosuppressants
 Cyclosporine6Gengraf, Neoral, etc.
 Everolimus1Certican
 Sirolimus1Rapamune
 Mycophenolate mofetil2Cellcept, Mucoloc
Calcium Channel Blockers
 Amlodipine7Amlocard, Amlodis, etc.
 Benidipineb--
 Nicardipine3Cardene, Cardene IV, etc.
 Nifedipine106Adalat, Adalat 10, etc.
Anticonvulsants
 Carbamazepine29Apo-Carbamazepine, Atretol, etc.
 Clobazam6Chlorepin, Clorepin, etc.
 Diazepam116Alboral, Aliseum, etc.
 Gabapentin3Aclonium, Neurontin, etc.
 Levetiracetam1Keppra
 Phenobarbital138Adonal, Aephenal, etc.
 Phenytoin130Aleviatin, Antisacer, etc.
 Primidone36Apo-Primidone, Cyral, etc.
 Topiramate2Topamax, Topamax Sprinkle, etc.
 Valproic acid25Alti-Valproic, Avugane, etc.
 Zonisamide4Excegran, Exegram, etc.

a Generic name and brand name were used in this analysis b Benidipine exists only generic name

Hatahira H., Abe J., Hane Y., Matsui T., Sasaoka S., Motooka Y., Hasegawa S., Fukuda A., Naganuma M., Ohmori T., Kinosada Y, & Nakamura M. (2017). Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. Journal of Pharmaceutical Health Care and Sciences, 3, 19.
Full text: Click here
Publication 2017
Adalat Amlodipine Amlodis Anticonvulsants Antisacer benidipine Calcium Channel Blockers Carbamazepine Cardene Clobazam Diazepam Drug Reaction, Adverse Everolimus Gabapentin Generic Drugs Immunosuppressive Agents Levetiracetam Medical Devices Mycophenolate Mofetil Neoral Neurontin Nicardipine Nifedipine Patients Pharmaceutical Preparations Phenobarbital Phenytoin Primidone Sirolimus Topamax Topiramate Valproic Acid Zonisamide

Most recents protocols related to «Nicardipine»

1
HPLC-Based Protein Binding Estimation
Retention times of the analytes were measured with Shimadzu HPLC system on the CHIRALPAK®HAS stationary phase (50 × 3 mm, 5 μm, Chiral Technologies, DAICEL Group, Europe SAS, France). The mobile phase A consisted of 50 mM aqueous ammonium acetate buffer (pH 7.4) and phase B of 2-propanol according to Valko et al.65 (link) Analysis was performed at prolonged 1 mL min−1 flow rate in the linear gradient. Retention capacity factors (k′) were calculated by using DMSO or a substance with 0% HAS binding for systems' dead time (Rt0). The system was calibrated by injecting the reference compounds: acetylsalicylic acid (CAS 69-72-7), betamethasone (CAS 378-44-9), budesonide (CAS 5133-22-3), carbamazepine (CAS 298-46-4), cimetidine (CAS 51481-61-9), ciprofloxacin (CAS 85721-33-1), indomethacin (CAS 53-86-1), isoniazid (CAS 54-85-3), metronidazole (CAS 443-48-1), nicardipine (CAS 55985-32-5), nizatidine (CAS 76963-41-2) and warfarin (CAS 81-81-2) obtained from Sigma-Aldrich, diclofenac (CAS 15307-86-5) from EMD Chemicals Inc., flumazenil (CAS 78755-81-4) from ABX and ketoprofen (CAS 22071-15-4) from LKT Labs. The logarithmic capacity factors of the references' Rt (log(k′)) on the HSA column were plotted against the %PPB values from literature. The slope and the intercept were used to convert the log(k′) of the compounds (6a, c, f, h, m–o) to %PPB using the regression equation.66 (link)
Dzedulionytė K., Fuxreiter N., Schreiber-Brynzak E., Žukauskaitė A., Šačkus A., Pichler V, & Arbačiauskienė E. (2023). Pyrazole-based lamellarin O analogues: synthesis, biological evaluation and structure–activity relationships. RSC Advances, 13(12), 7897-7912.
Full text: Click here
Publication 2023
ammonium acetate Aspirin Betamethasone Budesonide Buffers Carbamazepine Cimetidine Ciprofloxacin Diclofenac Flumazenil High-Performance Liquid Chromatographies Indomethacin Isoniazid Ketoprofen Metronidazole Nicardipine Nizatidine Propanols Retention (Psychology) Sulfoxide, Dimethyl Warfarin
2
Factors Influencing Bepridil Plasma Concentrations
The collection time of the plasma sample included data from before administration of bepridil to up to 6 h after administration. To assess risk factors for achieving plasma bepridil concentrations ≥800 ng/mL at steady state, the eligible patients were divided into two groups based on their bepridil concentrations: ≥800 ng/mL and < 800 ng/mL.
The C/D ratio was calculated using the following equation:
C/D ratio of bepridil = plasma concentration of bepridil (ng/mL) / dose of bepridil (mg/day/kg body weight).
In this study, we defined the polypharmacy group as those who use six or more drugs, whereas the non-polypharmacy group was those who took fewer than six drugs. The relationship between plasma bepridil concentrations ≥800 ng/mL and baseline characteristics, including sex, age, height, body weight, body mass index, serum creatinine, creatinine clearance (Ccr), number of concomitant drugs used, typical inducers of CYPs (phenytoin, carbamazepine, phenobarbital, and rifampicin) [15 (link)], typical inhibitors of CYPs (erythromycin, clarithromycin, protease inhibitors, and azole antifungals) [15 (link)], aprindine, a competitive inhibitor of CYP2D6 [12 (link)], typical inhibitor of P-gp (amiodarone, diltiazem, nicardipine, nifedipine, propranolol, quinidine, cyclosporin, and tacrolimus) [16 (link)–18 (link)], and left ventricular ejection fraction (LVEF), were examined. LVEF was measured using echocardiographic equipment provided at each hospital. Ccr was estimated using the Cockcroft–Gault formula [19 (link)].
The patient’s medical history and duration of bepridil treatment were collected from medical records.
Asai Y., Arihara H., Omote S., Tanio E., Yamashita S., Higuchi T., Hashimoto E., Yamada M., Tsuji H., Kondo Y., Hayashi M, & Yamamoto Y. (2023). Effect of polypharmacy on plasma bepridil concentration in patients with heart failure: a multicenter retrospective study. Journal of Pharmaceutical Health Care and Sciences, 9, 10.
Full text: Click here
Publication 2023
Amiodarone Antifungal Agents Aprindine Azoles Bepridil Body Weight Carbamazepine Clarithromycin Creatinine Cyclosporine Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P450 Diltiazem Echocardiography Erythromycin Index, Body Mass inhibitors Nicardipine Nifedipine Patients Pharmaceutical Preparations Phenobarbital Phenytoin Plasma Polypharmacy Propranolol Protease Inhibitors Quinidine Rifampin Serum Specimen Collection Tacrolimus Ventricular Ejection Fraction
3
Comprehensive Intraoperative Monitoring and Management
The surgical procedure was performed under general anesthesia. The ECG, heart rate, arterial blood pressure, SpO2, urine volume, end-tidal carbon dioxide pressure (ETCO2), and depth of anesthesia were measured continuously upon entering the operation room for all patients. According to the results of blood gas analysis and gas monitoring, the respiratory rate or tidal volume was adjusted to maintain ETCO2 at 35 ~ 45 mmHg. Intraoperative heat preservation treatment was performed as follows: the body temperature was maintained at 36 ~ 37 ℃. If the patient’s blood pressure was 30% lower than the blood pressure base value or systolic blood pressure was lower than 80 mmHg, an intravenous pump with a small dose of norepinephrine (0.2 ~ 0.4 µg kg−1 h−1) was used. Nicardipine was intravenously injected at 10 µg kg−1 to maintain intraoperative blood pressure within the normal range if blood pressure was 30% higher than the base value or systolic pressure was higher than 160 mmHg. When the patient’s heart rate was lower than 50 beats h−1, atropine was intravenously injected at 0.5 µg kg−1, and when the heart rate was higher than 100 beats h−1, 0.5 mg kg−1 esmolol was slowly injected intravenously. If the intraoperative COP was < 20 mmHg, furosemide 5 mg was intravenously injected.
Feng A., Lu P., Yang Y., Liu Y., Ma L, & Lv J. (2023). Effect of goal-directed fluid therapy based on plasma colloid osmotic pressure on the postoperative pulmonary complications of older patients undergoing major abdominal surgery. World Journal of Surgical Oncology, 21, 67.
Full text: Click here
Publication 2023
Anesthesia Atropine Biologic Preservation Blood Gas Analysis Blood Pressure Body Temperature Carbon dioxide esmolol Furosemide General Anesthesia Nicardipine Norepinephrine Patients Pressure Rate, Heart Respiratory Rate Saturation of Peripheral Oxygen Systolic Pressure Tidal Volume Urine
4
Remifentanil Anesthesia Management Protocols
After entry to the operating room, HR, BP, and peripheral oxygen saturation were recorded for all patients; subsequently, dexamethasone 0.1 mg/kg and glycopyrrolate 0.005 mg/kg were administered. After pre-oxygenation, propofol 2 mg/kg and rocuronium 0.8 mg/kg were administered. The anesthesia was maintained with desflurane and was adjusted according to the bispectral index (BIS) level goal, which is from 30 to 60.
In the case of the T group, the Ce of remifentanil before intubation was set to 5.0–7.0 ng/mL using the syringe pump with a Minto model (Orchestra® Base Primea, Fresenius Kabi, VL, France) [17 (link)]. During surgery, the patients’ BP and HR were monitored, and the Ce of remifentanil was adjusted within the range of 1.0–3.0 ng/mL. In the M group, 0.7–1 µg/kg of remifentanil was administered before intubation using an infusion pump (Terufusion® Infusion Pump, Terumo, Tokyo, Japan). During surgery, remifentanil was titrated within the range of 0.05–0.2 µg/min/kg against HR and BP within a 20% range of baseline measurements. In both groups, if vital signs could not be controlled by remifentanil alone, a vasoconstrictor (phenylephrine, 50 µg) or vasodilator (nicardipine, 500 µg) was administered.
Remifentanil was discontinued during skin closure, and desflurane was discontinued when the position was changed from lithotomy to supine after surgery, and glycopyrrolate 0.005 mg/kg and pyridostigmine 0.25 mg/kg were administered as reversal agents of neuromuscular blockers. At the end of surgery, fentanyl-based (17.5 µg/kg) intravenous patient-controlled analgesia was administered to all of the participants until POD2. Additional opioids or analgesics were administered when patients complained of pain with an NRS pain score of ≥3 or if the patient required analgesics. In the PACU, fentanyl was administered as a bolus dose of 1 µg/kg. On POD1, intravenous acetaminophen 750 mg and per os ibuprofen 200 mg were used, and on POD2, ibuprofen was administered alone.
Lee S., You A.H., Kim M, & Kang H.Y. (2023). Postoperative Nausea and Vomiting According to Target-Controlled or Manual Remifentanil Infusion in Gynecological Patients Undergoing Pelviscopic Surgery: A Randomized Controlled Trial. Journal of Personalized Medicine, 13(2), 176.
Full text: Click here
Publication 2023
Acetaminophen Analgesics Analgesics, Opioid Anesthesia Cell Respiration Desflurane Dexamethasone Fentanyl Glycopyrrolate Ibuprofen Infusion Pump Intubation Neuromuscular Blocking Agents Nicardipine Operative Surgical Procedures Pain Patient-Controlled Analgesia Patients Phenylephrine Propofol Pyridostigmine Remifentanil Rocuronium Saturation of Peripheral Oxygen Signs, Vital Skin Syringes Vasoconstrictor Agents Vasodilator Agents
5
Nicardipine Oral Formulation Use in Children
Children who were treated with the previous nicardipine hydrochloride 2 mg/mL oral formulation in our center from 1 January 2020 to 31 December 2020 were identified using an internal compounding software program. Electronic medical files (CDP2® software, C.PAGE patient files) and prescriptions were consulted to collect demographic data and the prescribed doses of nicardipine. The study obtained ethics approval provided by the institutional ethics committee (CERDE-HLJ: Comité d’Ethique pour la Recherche sur Données Existantes et/ou Hors Loi Jardé) with the number E2023-02.
Cavelier M., Gondé H., Costa D., Lamoureux F., Pereira T., Buchbinder N., Varin R, & Hervouët C. (2023). Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension. Pharmaceutics, 15(2), 446.
Full text: Click here
Publication 2023
Child Hydrochloride, Nicardipine Institutional Ethics Committees Nicardipine Patients Prescriptions

Top products related to «Nicardipine»

1
Nicardipine by Merck Group
Sourced in United States, Australia, United Kingdom, Israel, Sao Tome and Principe
Nicardipine is a laboratory product manufactured by Merck Group. It is a calcium channel blocker used for research purposes.
2
Vx 2500 multi tube vortexer by Avantor
Sourced in United States
The VX-2500 multi-tube vortexer is a laboratory equipment designed to mix and agitate multiple samples simultaneously. It features a robust motor that generates consistent vortex motion to thoroughly mix the contents of up to 6 sample tubes. The vortexer operates at adjustable speeds to accommodate a variety of sample viscosities and volumes.
3
1.0 cfi fluor lens by Nikon
Sourced in United States
The 60× 1.0 CFI Fluor lens is a high-performance objective lens designed for Nikon microscopes. It has a magnification of 60× and a numerical aperture of 1.0, which provides excellent optical performance and resolution. The lens is part of Nikon's CFI (Chromatic-aberration-Free Infinity) optical system, ensuring optimal image quality and color fidelity.
4
Eclipse e600fn microscope by Nikon
Sourced in United States
The Eclipse E600FN is a microscope designed for high-performance imaging. It features a modular design and advanced optics to provide clear, detailed images. The microscope is suitable for a range of applications, including research and analysis. Specific details on the intended use or features of the product are not available.
5
Verapamil by Merck Group
Sourced in United States, Germany, France, United Kingdom, China, Japan, Spain, Italy, Sao Tome and Principe, Switzerland, Australia, Ireland, Belgium
Verapamil is a laboratory product manufactured by Merck Group. It is a calcium channel blocker that inhibits the movement of calcium ions through cell membranes, which can affect various physiological processes. The core function of Verapamil is to serve as a research tool for the study of calcium-dependent mechanisms in biological systems.
6
Isradipine by Bio-Techne
Sourced in United States
Isradipine is a laboratory research compound that functions as a calcium channel blocker. It is commonly used in scientific research to study the effects of calcium channel modulation on cellular processes.
7
Csu w1 spinning disk by Yokogawa
Sourced in Japan, United States
The CSU-W1 spinning disk is a high-speed confocal scanning unit designed for live-cell imaging applications. It features a Nipkow-type spinning disk that rapidly scans the sample, enabling rapid image acquisition with low phototoxicity. The device is compatible with a wide range of microscopes and can be integrated into various imaging systems.
8
Borealis system by Oxford Instruments
Sourced in United Kingdom
The Borealis system is a high-performance electron paramagnetic resonance (EPR) spectrometer developed by Oxford Instruments. It is designed to provide precise and reliable characterization of materials and samples through the detection and analysis of unpaired electrons. The system offers advanced capabilities for scientific research and industrial applications, enabling users to obtain detailed information about the structure, properties, and behavior of their samples.
9
Metamorph software by Molecular Devices
Sourced in United States, Japan, Germany, United Kingdom, Canada, France, Azerbaijan
MetaMorph software is a comprehensive image analysis platform designed for life science research. It provides advanced tools for acquiring, processing, and analyzing digital images from a variety of microscopy techniques. The software's core function is to enable researchers to quantify and extract meaningful data from their experimental images.
10
Gsk 7975a by Aobious
Sourced in United States
The GSK 7975A is a laboratory instrument used for analytical and research purposes. It is designed to perform specific tasks related to the analysis and study of chemical compounds. The core function of the GSK 7975A is to provide precise and reliable data for scientific investigations, but the details of its intended use are not provided.

More about "Nicardipine"

Nicardipine is a pharmaceutical agent belonging to the class of calcium channel blockers (CCBs), also known as calcium antagonists.
It is primarily utilized to manage hypertension (high blood pressure) and angina pectoris (chest pain).
Nicardipine works by relaxing and dilating blood vessels, which in turn reduces the workload on the heart and improves blood flow and oxygen supply.
This cardiovascular medication is commonly prescribed for its vasodilatory properties.
In addition to its established use in cardiovascular conditions, nicardipine has also been investigated for its potential neuroprotective effects in various neurological disorders.
Researchers are exploring the possibility of using nicardipine to mitigate the consequences of stroke and potentially slow the progression of Alzheimer's disease.
These investigations highlight the versatility and broad therapeutic applications of this calcium channel blocker.
To optimize nicardipine research, scientists can leverage the AI-driven platform offered by PubCompare.ai.
This innovative tool allows researchers to locate relevant protocols from the scientific literature, preprints, and patent databases, enabling them to identify the best procedures for enhanced reproducibility and accuracy.
By utilizing PubCompare.ai's advanced capabilities, researchers can streamline their nicardipine-related studies and gain valuable insights to advance their understanding of this important pharmaceutical agent.
Nicardipine-based research may also involve the use of related compounds, such as VX-2500 (a multi-tube vortexer), 60× 1.0 CFI Fluor lens (for microscopy), Eclipse E600FN microscope, Verapamil (another calcium channel blocker), Isradipine (a dihydropyridine calcium channel blocker), CSU-W1 spinning disk (for live-cell imaging), Borealis system (for multi-modal microscopy), MetaMorph software (for image analysis), and GSK 7975A (a TRPM2 channel inhibitor).
The careful selection and integration of these complementary tools and techniques can greatly enhance the quality and impact of nicardipine-focused research projects.